English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

BACKGROUND CSF-CTC testing using the CellSearch® platform is a validated diagnostic tool for leptomeningeal metastases (LM) from solid tumors. CSF-CTCs can also be detected in patients with brain metastases (BM), but their significance is unclear. Our objective was to evaluate the utility of CSF-CTC measurement in predicting outcomes in CNS metastases. METHODS We conducted a retrospective single-institution review of patients who underwent CSF-CTC testing from 2016–2019. Information on neuroaxis imaging, CSF results, systemic cancer status, tumor molecular profile and survival was collected. LM was diagnosed by unequivocal MRI findings and/or positive or suspicious CSF cytology. Survival analyses were performed using Cox proportional hazards modeling, and CSF-CTC splits associated with survival were identified through recursive partitioning analysis. RESULTS A total of 407 patients (38% lung primary, 34% breast, 28% other tumor types) were included; of these, 144 had LM and 233 had BM diagnosed before or around the time of CSF analysis (97 had both). We identified a subgroup of newly diagnosed CNS metastases, comprising 144 patients with LM, BM, or both diagnosed within 30 days of CSF sampling: 70 patients with LM, 43 with BM, and 31 with both. For 101 patients with newly diagnosed LM, mean and median CSF-CTCs were 127.3 and 200, respectively, compared to 44.6 and 0 in the overall cohort; 73/101 had positive (66) or suspicious (7) cytology. CSF-CTCs predicted survival in patients with newly diagnosed LM, with optimal cutoff identified at 61 CSF-CTCs, above which the risk of death doubled (HR=2.09, 95% CI: 1.13–3.87, p=0.02). For this group, positive/suspicious cytology was also associated with higher risk of death, but this result was not statistically significant (HR=1.79, 95% CI: 0.95–3.35, p=0.07). CONCLUSION In newly diagnosed LM, quantification of CSF-CTCs predicts survival. CSF-CTC measurement can be used as a prognostic tool in patients with CNS metastases.

57. CIRCULATING TUMOR CELLS (CTC) IN CEREBROSPINAL FLUID (CSF) AS A PREDICTOR OF SURVIVAL IN CNS METASTASES